Menu
Search
|

Menu

Close
X

Codexis Inc CDXS.OQ (NASDAQ Stock Exchange Global Select Market)

9.10 USD
+0.12 (+1.39%)
As of Feb 23
chart
Previous Close 8.98
Open 9.05
Volume 23,667
3m Avg Volume 50,801
Today’s High 9.20
Today’s Low 8.90
52 Week High 9.40
52 Week Low 3.70
Shares Outstanding (mil) 48.35
Market Capitalization (mil) 439.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
28
FY16
49
FY15
42
EPS (USD)
FY17
-0.526
FY16
-0.214
FY15
-0.200
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
11.50
8.35
Price to Book (MRQ)
vs sector
19.91
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
1.63
15.84
LT Debt to Equity (MRQ)
vs sector
1.63
12.39
Return on Investment (TTM)
vs sector
-108.58
13.63
Return on Equity (TTM)
vs sector
-130.10
15.39

EXECUTIVE LEADERSHIP

Bernard Kelley
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Thomas Baruch
Chairman Emeritus, Since 2016
Salary: --
Bonus: --
John Nicols
President, Chief Executive Officer, Director, Since 2012
Salary: $592,000.00
Bonus: $404,000.00
Gordon Sangster
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $121,875.00
Bonus: $44,000.00
Douglas Sheehy
Executive Vice President, Chief Administrative Officer, General Counsel, Secretary, Since 2014
Salary: $385,396.00
Bonus: $178,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Penobscot Dr
REDWOOD CITY   CA   94063-4718

Phone: +1650.4218100

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

SPONSORED STORIES